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Subcutaneous peginterferon β-1a
injection-site reaction experience
and mitigation: Delphi analysis of the
ALLOW study
Barry Hendin*,1, DeRen Huang2, Sibyl Wray3, Robert T Naismith4, Sheri Rosenblatt5,
Javier Zambrano6 & Brian Werneburg6
Summary Points

●●

Healthcare professionals agreed that erythema is the most common injection-site reaction (ISR) associated with
peginterferon β-1a treatment.

●●

The healthcare professionals felt that the erythema was not disruptive to the patients’ daily activities.

●●

Education provided by healthcare professionals is vital for managing patients’ expectations about the potential
for developing ISRs, alleviating anxiety when these adverse events occur and providing guidance on management
strategies.

●●

It was agreed that an on-site conversation with a clinician was considered to be the best way to deliver education.

●●

Survey respondents mostly agreed that medication for mitigation of ISRs was not needed.

●●

Informing patients about the timing, impact, and management of ISRs may help to optimize treatment adherence
and clinical outcomes with peginterferon β-1a.

Aim: The objective of this Delphi analysis was to obtain consensus on injection-site
reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting
multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in
the ALLOW Phase IIIb trial using a three-step approach. Methods: Study investigators and
coordinators from investigative sites enrolling four or more patients in ALLOW participated
in three rounds of questionnaires and interviews. Results: Respondents (n = 37) agreed that
the most common ISR, erythema, was not disruptive to daily activities. Patient education,
as a conversation with a clinician about ISR potential, was recommended. Conclusion: The
consensus of Delphi respondents on ISR experience and ISR management after switching
from nonpegylated IFNs to peginterferon β-1a can help inform treatment decisions and
manage patient expectations.
First draft submitted: 19 July 2016; Accepted for publication: 21 October 2016; Published
online: 10 January 2017
Patient adherence to disease-modifying treatments (DMTs) in multiple sclerosis (MS) is important
for optimizing clinical outcomes and minimizing healthcare burden [1–4] . However, factors associated with parenteral administration of DMTs, such as frequency of administration and adverse
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events (AEs), are major barriers to adherence in
patients with MS [5–7] . Large observational studies have shown that DMTs with more frequent
administration are associated with lower adherence than those administered less frequently:
adherence rates of 49−79% were reported with
once-daily subcutaneous (sc.) glatiramer acetate
versus 77−94% for once-weekly intramuscular
IFN β-1a [7–11] . Injection-site reactions (ISRs) are
among the most common AEs leading to switching from or discontinuing a DMT [5,12] , and they
can occur frequently [13] . In a recent open-label,
prospective observational study, more than 55%
of patients receiving sc. interferons or glatiramer
acetate experienced ISRs [13] .
Peginterferon β-1a (pegylated IFN β-1a),
administered sc. every 2 weeks is approved for
the treatment of relapsing MS (RMS, in the
USA) and relapsing-remitting MS (RRMS, in
the EU), based on results from the ADVANCE
Phase III pivotal study [14] . Peginterferon β-1a
demonstrated significant improvements in several clinical and MRI efficacy end points compared with placebo, and a safety profile consistent with other β IFNs, with a lower dosing
frequency than other available DMTs [14–16] .
The most common AEs were flu-like symptoms (FLS) and ISRs, and erythema was the
most frequently reported ISR, occurring in
62% of patients at 48 weeks [15] and 64% of
patients at 2 years [16] during treatment with sc.
peginterferon β-1a every 2 weeks.
Understanding the impact and management
of ISRs associated with peginterferon β-1a therapy may help to improve patient adherence and
clinical outcomes [1,2,6,7,17] . The Delphi technique, which is a well established methodology
for building consensus through iterative rounds
of questionnaires [18] , was utilized to better characterize ISRs reported during the ADVANCE
study and to identify management strategies for
these AEs [19] . ADVANCE study investigators
with a predefined number of enrolled patients
participated in a consensus generating exercise
using a modified, two-round, sequential Delphi
technique. Overseen by an independent steering
committee of expert clinicians, questionnaires
were developed to evaluate the frequency, duration, impact and management of ISRs (questionnaire one) and then, based on the responses
to the first questionnaire, to gain consensus
on the impact and management of these AEs
(questionnaire two). Responders agreed that
ISR frequency reduced with time, erythema
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was the most common ISR, and the impact of
ISRs on activities of daily living was minimal.
Nonpharmacological management strategies
were recommended for ISRs, including rotation
of injection site, patient education, administering peginterferon β-1a at room temperature and
cooling the injection site after injection.
Specific ISR characteristics were not obtained
in the peginterferon β-1a ADVANCE study.
Although the ADVANCE Delphi analysis provides important information about peginterferon β-1a related ISRs, this study was unable to
obtain consensus on ISR onset or duration [15,19] .
Additionally, the ADVANCE patient population was almost completely IFN naive; therefore,
the impact of ISRs in patients switching from
nonpegylated IFN therapies to peginterferon
β-1a has not been investigated. The Phase IIIb
ALLOW study (NCT01939002) is an ongoing,
multicenter, open-label, randomized study being
conducted in the USA to characterize FLS and
other AEs in RMS patients who switch from
nonpegylated interferon-β therapies to sc.
peginterferon β-1a. The objective of the analysis reported in this study was to gain further
understanding from clinical trial researchers
of the experience and impact of peginterferon
β-1a-related ISRs and to obtain consensus on
the most effective mitigation strategies for ISRs
in relapsing-remitting MS patients switching
from nonpegylated IFN therapies by applying
the Delphi method to the ALLOW study using
a three-step process.
Methods
In this study we performed a three-step decisionmaking process to build consensus, from study
personnel taking part in the ALLOW study, on
ISR experience and impact, to identify potential
strategies to manage the most common ISRs and
to rank patient education delivery methods. To
obtain consensus, we combined quantitative and
qualitative methods (online survey, qualitative
telephone interviews).
●●ALLOW study

The ALLOW study included patients aged
18–65 years with a confirmed diagnosis of
RMS (defined by McDonald criteria [20,21]), an
Expanded Disability Status Scale score between
0.0 and 5.0, and who had been receiving a stable dose of IFN-β therapy for ≥4 months. After
a 4-week run-in period during which patients
remained on their nonpegylated IFN therapy,
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patients were switched to sc. peginterferon
β-1a administered every 2 weeks, randomized
to either their current FLS treatment or naproxen. The peginterferon β-1a dose was titrated
from 63 mcg at baseline to 125 mcg at week 4
and this dose was maintained to week 48. The
primary objective of the ALLOW study was
to determine the proportion of patients who
experience new and/or increased FLS after
switching from nonpegylated IFN-β therapies
to sc. peginterferon β-1a. Secondary objectives included evaluating the incidence and
frequency of other AEs throughout the study
period. The ALLOW study was conducted in
accordance with the Declaration of Helsinki,
the International Conference on Harmonization
and Good Clinical Practice guidelines and local
regulatory requirements.
Of 201 patients randomized, 164 (81.6%
within each arm) completed the ALLOW study.
●●Delphi study participants

Investigative sites with at least four patients
enrolled in the ALLOW clinical trial were identified by the study medical team and invited by
email to participate in the Delphi study. The
sites handled by the principal investigators
(PIs) in the steering committee were excluded
from the study. The only information collected
about participants was name, role (PIs or study
coordinators [SCO]) and contact information.
●●Material & data collection

Three sequential rounds of questionnaires and
qualitative interviews (only round 3 generated
quantitative data) were administered to PIs and
SCOs. Development of the surveys and qualitative interview questions were overseen by an
independent steering committee of four neurologists, who are also authors of this manuscript (B Hendin, DR Huang, S Wray and RT
Naismith). At each stage, the steering committee
convened to review the data to see if consensus
had been achieved and recommend next steps.
In an effort to achieve consensus, each of the
three rounds of the study built on the insights
obtained in the previous round . In theory,
consensus could be achieved in any round.
Round 1 was an online survey (Supplementary
Figure 1) built in Survey Monkey, designed to
obtain opinion on ISR experience and impact,
as well as an initial assessment of potential
strategies for resolving the most common ISRs.
Open-ended questions were used throughout as
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a vehicle to encourage unguided ideas. A pilot
of this survey was conducted with one PI and
one SCO. The first round yielded the following
qualitative issues for round 2: understand what
is driving attitudes toward ISRs and understand
perceptions of suggested approaches.
Round 2 comprised qualitative telephone
interviews with round 1 responders and nonresponders to gain further insight into ISR
experience and to obtain consensus on the most
effective mitigation strategies for peginterferon
β-1a-related ISRs. The discussion guide for round
2 has been provided as Supplementary Figure 2.
Since the steering committee decided that consensus had not been achieved, it recommend an
online survey similar to round 1 as the next step,
and recommended additional topics, including
detailed definition of patient education, and
explanation of injection-site rotation.
Round 3 was an online survey designed to
assess ISR experience and provide quantified
validation of the recommended mitigation strategies for peginterferon β-1a-related ISRs. The
online survey for round 3 has been provided as
Supplementary Figure 3.
●●Data analysis

Delphi analysis results were derived from participants’ responses to the round 3 survey statements about ISR experience and mitigation
strategies. Statements were rated by reviewers
and the means of all ratings were determined.
Most statements were rated on a 1–10 rating
scale, because it is more sensitive at measuring

Figure 1. Respondents and trial site participation in each round of the ALLOW
Delphi study.

www.futuremedicine.com

41

Research Article Hendin, Huang, Wray et al.
differences (smaller sample size required for the
same degree of precision), has greater statistical
reliability and validity, has been used in previous
Delphi analyses, and is preferred by respondents
compared with a scale with fewer points [22] . An
online self-administered questionnaire allows
use of rating scales that can be analyzed with
standard metrics – mean and percentages –
which in turn can be turned into tables and
graphs. Qualitative results require more subjective interpretation, typically supported by
respondent quotes. The use of both analytic
approaches combines objective measures with
the richness of deeper insight.
Results
●●Study sites & participants

All of the ALLOW trial sites (n = 17) with at
least four patients enrolled participated in at
least one round of the ALLOW Delphi study
(Figure 1) ; in total, 37 responded (13 PIs, 24
SCOs). The trial sites responding accounted for
greater than 80% of the 201 patients enrolled
in the 48 week ALLOW trial: patient mean age
was 50 years; gender was 81% female; race was
90% Caucasian and 8% African–American;
mean MS duration was 13.5 years. At the time
when the surveys and interviews were carried
Statement

out, the study data on ISR frequency at their
site or throughout the study were not available
to any of the researcher participants.
●●Consensus achieved

The results following the three-step process
are presented below. Consensus was achieved
following the third round of data collection.
●●ISR experience

For patients starting on peginterferon β-1a, the
researcher respondents agreed that erythema
was the most common ISR (mean agreement:
8.95/10) but was not disruptive to the patients’
daily activities (8.58/10; Figure 2). Onset of erythema was often delayed following injection,
typically by more than 24 h (9.00/10; Figure 2),
with 89.4% of responders indicating an onset
after 1−4 days (Table 1) . However, there were
lower levels of agreement that the delayed onset
of erythema was unexpected (6.32/10; Figure 2).
Respondents indicated that erythema lasted
longer than expected, usually >3 days (8.63/10;
Figure 2), with the majority of PIs reporting that
the median duration of erythema was 7−9 days,
and the majority of SCOs reporting that the
median duration of erythema was 12−14 days
(Figure 3) , and that duration of erythema was

1 = Do not agree

10 = Strongly agree
8.95

For most patients starting on peginterferon β-1a,
the most common ISR was erythema

8.58

While erythema was common, it was usually
not disruptive to the patient’s daily activities

9.00

The onset of erythema was often delayed
after injection, typically for more than 24 h

8.63

For many patients, the erythema lasted longer
than expected, usually more than 3 days
7.74

The duration of erythema was longer
than most patients had experienced with
ISRs from previous interferon therapies

7.58

Other injection site reactions reported are pruritus,
pain, edema, and bruising. These ISRs tend
to occur much less frequently than erythema
For many patients, the delayed
onset of erythema was unexpected

6.32

Figure 2. Consensus on injection-site reaction experience in patients switching to subcutaneous peginterferon β-1a. Data are
presented as the means of all responder ratings. Consensus was achieved following round 3.
ISR: Injection-site reaction.
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Table 1. Typical onset of erythema after switching to subcutaneous peginterferon β-1a.
Erythema onset
Within 24 h
1–2 days
3–4 days
5–6 days
7 days or more
Total responses

Proportion of respondents reporting typical delay (%)
Study co-ordinators (n = 15) Primary investigators (n = 4)

Overall (n = 19)

6.7
26.7
60.0
6.7
0
100

5.3
36.8
52.6
5.3
0
100

0
75.0
25.0
0
0
100

Consensus was achieved following round 3.

longer than patients experienced with other IFN
therapies (7.74/10). SCOs and PIs appeared to
be in agreement about erythema prevalence,
impact, onset and duration, although fewer PIs
participated in round 3 (n = 4).
●●ISR mitigation strategies

As a general strategy, patient education about
the potential for developing ISRs was agreed
to be effective for diminishing patient anxiety when ISRs did occur (mean agreement:
9.11/10; Figure 4). High levels of agreement were
also found for the following preinjection statements: reassuring patients that redness is common, often delayed, and usually does not disrupt
daily activities, is important (9.63/10); illustrations of a range of erythema/redness will help
set expectations (8.68/10); and using injection

sites that are less visible can address the cosmetic
issue of redness (8.16/10; Figure 4). Regarding
postinjection statements, consensus was reached
that while injection site rotation is advisable, redness may persist for many patients (9.00/10) and
patient follow-up after the first injection will help
ensure that ISRs are not causing more concern
than expected (8.42/10; Figure 4 ). Agreement
regarding postinjection intervention strategies
was varied, with consensus that medication is
not required for most patients if expectations
for erythema/redness are managed in advance
(9.16/10), although nonsteroidal anti-inflammatory drugs can be taken as needed for pain
(8.16/10). Less agreement was met regarding
whether diphenhydramine or hydrocortisone
cream can be helpful for relieving pruritus
(6.00/10; Figure 4).

100
Overall
Study coordinators
Principal investigators

90
80

75

Respondents (%)

70
60
50
40

40

32

30

26

25

20
16

20
11
7

10

13

0
1–3

4–6

7–9

13
11

7
5
10–12

12–14

> 14

Duration (days)

Figure 3. Typical duration of erythema after switching to subcutaneous peginterferon β-1a.
Consensus was achieved following round 3.
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Statement

1 = Do not agree

10 = Strongly agree
9.11

Above all, patient education about ISR potential
is an effective strategy to diminish anxiety when
ISRs occur, particularly when the onset is delayed
Reassuring patients that redness is common,
that is often delayed and that it is usually
not disruptive to daily activities is important

9.63

9.16

Medications are not required for most patients, if setting
expectations about erythema/redness is provided
9.00

While injection site rotation is advisable,
for many patients redness may still persist
8.16

The cosmetic issue (redness) can be
addressed, when needed, by recommending
injection sites that are less visible
Illustrations of a range of erythema/redness will help set
expectations and inform patients and their families that
these are ISRs and not an allergic reaction or an infection

8.68

A follow-up phone call after the first injection with
peginterferon β-1a will help ensure that ISRs are
not causing more concern than expected

8.42
8.16

For pain, NSAIDs can be taken as needed
For pruritus, diphenhydramine or hydrocortisone
cream has been found to be helpful

6.00

Figure 4. Consensus on mitigation strategies for injection-site reactions occurring after switching from nonpegylated IFNs to
subcutaneous peginterferon β-1a. Data are presented as the means of all responder ratings. Consensus was achieved following
round 3.
ISR: Injection-site reaction.

Clinician and nurse engagement were ranked
highest for delivering patient education (Table 2) .
An on-site conversation with a clinician was considered to be the best way to deliver education
by the highest percentage of responders (42.1%),
followed by review of a brochure (containing
images of ISRs) with injection training delivered
by a nurse (31.6%).
Data for discontinuations due to ISRs or FLS
and a correlation of this with mitigation strategies used, are not available for the subset of study
sites participating in this analysis. In the overall
study, 6.0% of patients discontinued treatment
due to ISRs and 2.5% due to FLS.
Discussion
Applying the Delphi technique in the ALLOW
clinical trial enabled consensus to be obtained
about the experience and management of ISRs
associated with peginterferon β-1a treatment
from the point of view of study researchers.
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ISRs are common AEs with injectable DMTs
and are a primary reason for treatment nonadherence and discontinuation [5,12,23–24] . In
ADVANCE, the most common ISR for patients
receiving peginterferon β-1a every 2 weeks in
year 1 was erythema (62%), followed by pain
(15%) and pruritis (13%) [15] . The present analysis demonstrated agreement among Delphi
responders that erythema is the most common ISR after treatment with peginterferon
β-1a, but that its impact is minimal, rarely disrupting patients’ daily activities or requiring
medication. Responders also agreed that onset
of erythema is often delayed by at least a day
and tends to last longer than patients expect.
Lower consensus was reached for whether erythema lasted longer than reported with other
IFN therapies or whether delayed onset was
unexpected.
Consistent with a wide body of previous research, consensus was reached among
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Delphi responders that patient education is
the most effective mitigation strategy for ISRs.
Therefore, before initiating treatment, patients
should be informed regarding the potential
occurrence of ISRs to help to set expectations
and alleviate anxiety, particularly since the
appearance of these adverse effects may often
be delayed [25,26] . One study on IFN therapy in
patients with RMS reported that MS patients
often expect to experience high levels of anxiety
before injections [27] . In a second study investigating patient expectations and experiences of
sc. IFN therapy, potential side effects were identified as one of the most common concerns [28] .
Ensuring that patients are well informed before
initiating treatment improves their treatment
experience and helps to prevent or delay treatment discontinuation [28] . The best way to
deliver patient education was considered to
be via an on-site conversation with a healthcare professional, primarily a clinician. Such
proactive involvement of clinicians in patient
education about MS treatment is likely to help
maximize adherence and optimize patient outcomes [8] . Education delivered by nurses was
also ranked highly, which supports previous
research demonstrating the benefits of proactive nurse contact to promote adherence during treatment with DMTs [29] . Optimizing the
quality of interaction with the healthcare team
will help patients feel comfortable communicating their worries about treatment, providing the opportunity to address concerns and
enhance adherence [25] .
The consensus reached about the minimal
impact of ISRs and recommendations of the use
of nonpharmacological management strategies
in the ALLOW Delphi study is consistent with
the findings from the Delphi analysis in the
ADVANCE study [19] . Moreover, the consensus
that erythema is the most common ISR is in
agreement with the AE profile for peginterferon

Research Article

β-1a in the ADVANCE clinical trial [15,16] and
also in an interim analysis of the first 12 weeks
of the ALLOW clinical trial, which reported
that 29% of patients developed injection-site
erythema after switching from nonpegylated
IFNs, with no cases of erythema or other ISRs
reported as severe [30] . As ISRs are related to
administration frequency, patients would be
expected to experience a lower frequency of
ISRs with peginterferon β-1a than other available DMTs, which are dosed 2−14-times more
often [14] . Reduced dosing frequency may help
to explain why peginterferon β-1a-related ISRs
were considered to have minimal impact by the
ALLOW and ADVANCE Delphi responders [19]
and low ISR-related discontinuation rates have
been reported in clinical trials [15–16,30] . The consensus that peginterferon β-1a-related erythema
has a delayed onset and tends to last longer than
expected is a novel finding of the present study,
as detailed characteristics of ISRs have not been
reported in clinical trials, and the ADVANCE
Delphi study did not reach consensus on ISR
onset or duration [19] .
The main limitations of this study are that the
number of participants was limited to the trial sites
with at least four patients enrolled in ALLOW and
that data collected in the first and third round of
the study were each based on surveys reliant on
participant recollection. However, the three-stage
sequential design of the study, the qualitative interview in the second round and the high degree of
consensus obtained in the third round support the
validity of our results. Another limitation of the
study is the variation in participation through each
round and the potential for different individuals
at a given site to be completing different rounds.
Additionally, as always, limited conclusion can
be drawn from studies employing self-reported
surveys and phone interviews. Further experience
with peginterferon β-1a in real world clinical
practice is needed to confirm these findings.

Table 2. Agreement on the best way to deliver patient education about injection-site reactions by study coordinators’ and
primary investigators’ responses combined.
Patient education method
On-site conversation with clinician
Brochure reviewed with nurse injection training‡
On-site conversation and brochure
Brochure to use on site in setting expectations about ISRs

Proportion of respondents giving ranking (n = 19); (%)†
1

2

3

4

Total

42.1
31.6
15.8
10.5

15.8
26.3
52.6
5.3

15.8
21.1
26.3
36.8

26.3
21.1
5.3
47.4

100
100
100
100

Ranking is in order of 1–4.
The brochure reviewed included pictures of ISRs.
ISR: Injection-site reaction.
†
‡
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Conclusion
Confirming and extending the pivotal Phase
III clinical trial results, the ALLOW Delphi
consensus data indicate that erythema is the
most commonly observed ISR associated with
peginterferon β-1a, but its impact on daily
activities is minimal, as judged by clinical
trial researchers. These data also highlight
that educating patients on the characteristics
and management of ISRs before starting treatment is considered important for setting treatment expectations, promoting adherence and
improving patient outcomes.
This study is the first to provide consensus
on ISR experience and mitigation strategies
in patients switching from nonpegylated IFN
therapies to peginterferon β-1a. The agreement
obtained on ISR management is consistent with
previously published recommendations for proactive patient education delivered by healthcare
professionals and has the potential to impact
clinical practice by ensuring optimal adherence to injections and improving therapeutic
outcomes.
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